Amna Kamil Leads Systematic Review on Factor Xa Inhibitors for Cancer-Associated VTE
Amna Kamil, MS5 at JSMU (Jinnah Sindh Medical University) posted on LinkedIn:
”Publication Alert
Alhamdulillah
Thrilled to announce that my first Systematic Review and Meta-analysis has been published as First Author in Clinical and Applied Thrombosis/Hemostasis (SAGE Journals)
Why this research matters:
Cancer patients face a much higher risk of developing venous thromboembolism (VTE) – a major cause of morbidity and mortality. Traditional anticoagulants (like LMWH or VKAs) have limitations, leading to growing interest in Factor Xa inhibitors (DOACs such as apixaban and rivaroxaban).
What we found:
Factor Xa inhibitors significantly reduced the risk of VTE compared to placebo.
However, they were also linked to a higher risk of major bleeding.
The balance between benefit and risk highlights the importance of individualized patient selection and the need for further large-scale trials.
This work contributes to ongoing discussions on optimizing thromboprophylaxis in high-risk cancer patients, aiming for safer and more effective clinical decision-making.
This marks a special milestone in my research journey. Grateful to my incredible co-authors and mentors for their constant support and teamwork throughout this process.”
Read the full article here.
Title: “Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis”
Authors: Amna Kamil, Sandhiya Prem Kumar, Rumaisa Zulfiqar, Eiman Araib, Bibi Samia Khan, Muhammad Saad Khan, Muhammad Mohsin Khan, Umaimah Naeem, Aminath Waafira
Stay updated with Hemostasis Today.
-
Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
-
Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
-
Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
-
Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
-
Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
-
Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry